Spyre Therapeutics
SYRE
SYRE
50 hedge funds and large institutions have $19.2M invested in Spyre Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
15% less capital invested
Capital invested by funds: $22.6M → $19.2M (-$3.38M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Holders
50
Holding in Top 10
1
Calls
$11K
Puts
–
Top Buyers
| 1 | +$1.04M | |
| 2 | +$472K | |
| 3 | +$415K | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$405K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$198K |
Top Sellers
| 1 | -$1.34M | |
| 2 | -$1.31M | |
| 3 | -$748K | |
| 4 |
Goldman Sachs
New York
|
-$482K |
| 5 |
BlackRock
New York
|
-$174K |